Humacyte, Inc. (HUMA) stock

HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 2/30

$0.56−0.04 (-6.21%)

Close on Nov 13, 2026Market cap $155.12MP/E –Yield –

Humacyte operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Humacyte's operating income for the twelve months ending Sep 30, 2026 was -$110.29M. For fiscal 2025 it was -$108.14M. The highest annual figure on record is -$64.60M in fiscal 2020.

Annual operating income

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-$108.14M	–
FY2024	Dec 31, 2024	-$114.40M	–
FY2023	Dec 31, 2023	-$100.05M	–
FY2022	Dec 31, 2022	-$84.58M	–
FY2021	Dec 31, 2021	-$81.21M	–
FY2020	Dec 31, 2020	-$64.60M	–

Quarterly operating income

Change is against the same quarter a year earlier.

Period	Period end	Value	Change
Q3 FY2026	Sep 30, 2026	-$23.52M	–
Q2 FY2026	Jun 30, 2026	-$27.00M	–
Q1 FY2026	Mar 31, 2026	-$28.94M	–
Q4 FY2025	Dec 31, 2025	-$30.84M	–
Q3 FY2025	Sep 30, 2025	-$24.39M	–
Q2 FY2025	Jun 30, 2025	-$29.73M	–
Q1 FY2025	Mar 31, 2025	-$23.18M	–
Q4 FY2024	Dec 31, 2024	-$28.09M	–
Q3 FY2024	Sep 30, 2024	-$30.23M	–
Q2 FY2024	Jun 30, 2024	-$29.50M	–
Q1 FY2024	Mar 31, 2024	-$26.58M	–
Q4 FY2023	Dec 31, 2023	-$26.18M	–
Q3 FY2023	Sep 30, 2023	-$24.62M	–
Q2 FY2023	Jun 30, 2023	-$26.73M	–
Q1 FY2023	Mar 31, 2023	-$22.51M	–
Q4 FY2022	Dec 31, 2022	-$20.79M	–
Q3 FY2022	Sep 30, 2022	-$23.49M	–
Q2 FY2022	Jun 30, 2022	-$18.53M	–
Q1 FY2022	Mar 31, 2022	-$21.76M	–
Q4 FY2021	Dec 31, 2021	-$21.63M	–
Q3 FY2021	Sep 30, 2021	-$20.54M	–
Q2 FY2021	Jun 30, 2021	-$19.27M	–
Q1 FY2021	Mar 31, 2021	-$19.77M	–
Q4 FY2020	Dec 31, 2020	-$15.67M	–
Q3 FY2020	Sep 30, 2020	-$17.21M	–